About: Development of mass spectrometry-based targeted assay for direct detection of novel SARS-CoV-2 coronavirus from clinical specimens

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Development of mass spectrometry-based targeted assay for direct detection of novel SARS-CoV-2 coronavirus from clinical specimens Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Development of mass spectrometry-based targeted assay for direct detection of novel SARS-CoV-2 coronavirus from clinical specimens
Creator	Pandey, Akhilesh Singh, Ravinder Dasari, Surendra Vanderboom, Patrick Chavan, Sandip Grebe, Stefan Gurtner, Kari Kemp, Jennifer Kipp, Benjamin Madden, Benjamin Madugundu, Anil Mangalaparthi, Kiran Maus, Anthony Mun, Dong-Gi Peterson, Jane Renuse, Santosh Singh, Smrita
Source	MedRxiv
abstract	The COVID-19 pandemic caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) has overwhelmed health systems worldwide and highlighted limitations of diagnostic testing. Several types of diagnostics including RT-PCR-based assays, antigen detection by lateral flow assays and antibody-based assays have been developed and deployed in a short time. However, many of these assays are lacking in sensitivity and/or specificity. Here, we describe an immunoaffinity purification followed by high resolution mass spectrometry-based targeted assay capable of detecting viral antigen in nasopharyngeal swab samples of SARS-CoV-2 infected individuals. Based on our discovery experiments using purified virus, recombinant viral protein and nasopharyngeal swab samples from COVID-19 positive patients, nucleocapsid protein was selected as a target antigen. We then developed an automated antibody capture-based workflow coupled to targeted high-field asymmetric ion mobility spectrometry (FAIMS) - parallel reaction monitoring (PRM) assays on an Orbitrap Exploris 480 mass spectrometer. An ensemble machine learning-based model for determining COVID-19 positive samples was created using fragment ion intensities in the PRM data. This resulted in 97.8% sensitivity and 100% specificity with RT-PCR-based molecular testing as the gold standard. Our results demonstrate that direct detection of infectious agents from clinical samples by mass spectrometry-based assays have potential to be deployed as diagnostic assays in clinical laboratories.
has issue date	2020-08-06(xsd:dateTime)
bibo:doi	10.1101/2020.08.05.20168948
has license	medrxiv
sha1sum (hex)	92593aaf4bcfeffbb4e06d5c8c9a7d3bca29b22f
schema:url	https://doi.org/10.1101/2020.08.05.20168948
resource representing a document's title	Development of mass spectrometry-based targeted assay for direct detection of novel SARS-CoV-2 coronavirus from clinical specimens
resource representing a document's body	covid:92593aaf4bcfeffbb4e06d5c8c9a7d3bca29b22f#body_text
is schema:about of	named entity 'workflow' named entity 'asymmetric' named entity 'SARS-CoV-2' named entity 'developed' named entity 'selected' named entity 'types' named entity 'protein' named entity 'detection' named entity 'mass' named entity 'specimens' named entity 'CLINICAL LABORATORIES' named entity 'INDIVIDUALS' named entity '100%' named entity 'CREATED' named entity 'worldwide' named entity 'monitoring' named entity 'SARS-CoV-2' named entity 'detection' named entity 'machine' named entity 'patients' named entity 'mass' named entity 'limitations' named entity 'antigen' named entity 'individuals' named entity 'diagnostic testing' named entity 'gold standard' named entity 'SARS-CoV-2' named entity 'Orbitrap' named entity 'RT-PCR' named entity 'viral protein' named entity 'FAIMS' named entity 'diagnostic testing' named entity 'recombinant' named entity 'PRM' named entity 'virus' named entity 'parallel reaction monitoring' named entity 'nasopharyngeal swab' named entity 'RT-PCR' named entity 'clinical laboratories' named entity 'diagnostic assays' named entity 'COVID' named entity 'health systems' named entity 'SARS-CoV-2' named entity 'mass spectrometry' named entity 'proteomic' named entity 'NIAID' named entity 'MS/MS' named entity 'helix structure' named entity 'SARS-CoV-2' named entity 'coronaviruses' named entity 'MERS' named entity 'SARS' named entity 'peptides' named entity 'mass spectrometer' named entity 'supervised machine learning' named entity 'capillary' named entity 'Odense' named entity 'infection' named entity 'SARS-CoV-2' named entity 'higher-energy collisional dissociation' named entity 'SARS-CoV' named entity 'nucleocapsid' named entity 'preprint' named entity 'nucleic acid' named entity 'capillary' named entity 'peptides' named entity 'Peptide' named entity 'clinical samples' named entity 'clinical samples'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software